New to Edison
Register today to access up-to-date company research.
Existing users
Log in to access company research.
Forthcoming events
Edison is an Event Partner participating at the following events:
London, 18-20 Nov 2008
London, 1-3 Dec 2008
Best Research Award 2007
Edison Investment Research, winners of 'Best Research Award'
Antisoma
| Date | Reports available | Download |
|---|---|---|
| Sep 19 2008 |
Novartis actions key Antisoma’s investment case pivots upon decisions to be taken over the next year by Novartis, in relation to ASA404. In particular, when or whether the Swiss group will initiate Phase III trials of the vascular disrupting agent in additional indications. Good news on this might result in additional milestone fees and drive the share price. There does however remain significant risk of an unfavourable outcome. Research type: Company Comment - Full year results |
Log in to download 8 page note available |
| Feb 25 2008 |
Novartis funding mitigates risk Antisoma is one of only a few companies in the UK biotech sector without a near-term funding requirement, boasting a significant cash balance thanks to a licensing deal signed with Novartis in April 2007. This to an extent mitigates the relatively high-risk nature of its business, and could enable it to grow through acquisitions as well as building up a US presence. Investors can expect significant clinical trial news flow to drive the share price over the coming months. Research type: Company Comment - Funding |
Log in to download 4 page note available |
| Oct 13 2005 |
Company Comment Antisoma is a biopharmaceutical company that is developing products for the treatment of cancer. Research type: Company Comment |
Log in to download 2 page note available |
- Register free to access the latest research.
- Contact us to find out how we help companies reach their investors.
IN THIS SECTION
Keep updated
Would you like to be notified when new research is published? Access our research RSS feed
Edison's research ... is balanced, objective and provides a level of detail not normally associated with smaller companies.
Peter Knowles
Director, Fyshe Horton Finney